36 completed, 2 terminated, 1 active not recruiting, 1 not yet recruiting. 41 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 41 | Completed 36, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 3 | Completed 2, Not yet recruiting 1 |
Follow evolocumab: new trials by email Literature Review of evolocumab trials Research Report on evolocumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy PCSK9 inhibitor - Acute Ischemic Stroke | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 478 | 2025-09-15 | 2025-09-15 |
| Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS) Evolocumab, Atorvastatin - Stroke Patients With Symptomatic Intracranial Atherosclerotic Stenosis | Phase 3 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 80 | 2023-04-15 | 2023-06-02 |
| Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19 Evolocumab, Saline solution - Sars-CoV-2 Infection | Phase 3 | Completed | Collegium Medicum w Bydgoszczy | 60 | 2021-06-01 | 2023-04-21 |
| Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients lerodalcibep, evolocumab, alirocumab - Hypercholesterolemia, Cardiovascular Diseases | Phase 3 | Completed | LIB Therapeutics LLC | 204 | 2021-04-22 | 2023-03-29 |
| Evolocumab in STEMI Repatha® - ST Elevation Myocardial Infarction | Phase 3 | Active not recruiting | Sejong General Hospital | 166 | 2020-12-05 | 2025-06-19 |
| Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH lerodalcibep, evolocumab - Homozygous Familial Hypercholesterolemia | Phase 3 | Completed | LIB Therapeutics LLC | 65 | 2019-12-07 | 2023-03-29 |
| Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Evolocumab, Placebo - Coronary Heart Disease (CHD) | Phase 3 | Completed | Amgen | 12301 | 2019-06-11 | 2026-06-25 |
| Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients Evolocumab, Placebo - Cardiac Allograft Vasculopathy | Phase 3 | Completed | Lars Gullestad | 130 | 2019-06-10 | 2023-11-01 |
| Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia evolocumab, placebo - Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Terminated | Amgen | 259 | 2019-05-09 | 2023-03-27 |
| Effect of Evolocumab on Coronary Atherosclerosis Evolocumab, 18F-NaF PET, CCTA - Cardiovascular Disease, Hyperlipidemia | Phase 3 | Completed | Cedars-Sinai Medical Center | 55 | 2019-03-19 | 2024-07-17 |
| Imaging of Coronary Plaques in Participants Treated With Evolocumab Evolocumab, Placebo, Statin therapy - Coronary Artery Disease (CAD) | Phase 3 | Completed | Amgen | 164 | 2018-11-19 | 2022-05-03 |
| PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients Evolocumab - Kideny Transplant Recipients With High Cardiovascular Risk Score | Phase 3 | Completed | Hamid Al-Essa Organ Transplant Center | 200 | 2018-05-01 | 2020-12-14 |
| EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) Evolocumab 140 mg/mL, Placebo - Acute Coronary Syndrome | Phase 3 | Completed | Insel Gruppe AG, University Hospital Bern | 308 | 2018-01-23 | 2019-08-14 |
| Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia Evolocumab, Placebo - Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection | Phase 3 | Completed | Amgen | 467 | 2017-05-22 | 2022-07-22 |
| Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia evolocumab, evolocumab and LDL apheresis, LDL apheresis - Hypercholesterolemia | Phase 3 | Completed | Hospital General Universitario Gregorio Marañon | 9 | 2017-04-01 | 2018-02-12 |
| Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries Evolocumab - Dyslipidemia | Phase 3 | Terminated | Amgen | 1600 | 2017-03-13 | 2024-05-29 |
| Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia) Evolocumab - Familial Hypercholesterolemia | Phase 3 | Completed | Amgen | 163 | 2016-09-10 | 2024-05-29 |
| Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension Evolocumab - Dyslipidemia | Phase 3 | Completed | Amgen | 5035 | 2016-09-02 | 2023-04-07 |
| Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia Evolocumab, Placebo to Evolocumab - Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Completed | Amgen | 424 | 2016-05-17 | 2018-08-31 |
| Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia Evolocumab, Atorvastatin, Placebo - Diabetes, Hyperlipidemia, Mixed Dyslipidemia | Phase 3 | Completed | Amgen | 986 | 2016-04-14 | 2019-01-11 |
Showing 20 of 41. Sign in to see all of them.
Hypercholesterolemia (26) · Hyperlipidemias (12) · Dyslipidemias (7) · Homozygous Familial Hypercholesterolemia (4) · Hyperlipoproteinemia Type II (4) · Cardiovascular Diseases (2) · Diabetes Mellitus (2) · Hypercholesterolemia, Autosomal Dominant, 3 (2) · Inhibition, Psychological (2) · Acute Coronary Syndrome (1) · COVID-19 (1) · Coronary Artery Disease (1) · Coronary Disease (1) · Diabetes Mellitus, Type 2 (1) · HIV Infections (1)
Amgen (30) · LIB Therapeutics LLC (2) · Cedars-Sinai Medical Center (1) · Collegium Medicum w Bydgoszczy (1) · Hamid Al-Essa Organ Transplant Center (1) · Hospital General Universitario Gregorio Marañon (1) · Insel Gruppe AG, University Hospital Bern (1) · Lars Gullestad (1) · Nanfang Hospital, Southern Medical University (1) · Sejong General Hospital (1) · The First Affiliated Hospital with Nanjing Medical University (1)
United States (28) · Canada (22) · Australia (19) · Belgium (17) · France (17) · Italy (17) · South Africa (17) · Spain (17) · Czechia (16) · Netherlands (16) · United Kingdom (15) · Germany (13) · Poland (13) · Denmark (12) · Hungary (12)
Evan A Stein, MD PhD (2) · Daniel S. Berman, MD (1) · Eliano Navarese, Md, PhD (1) · Hua Lu, MD (1) · Jacek Kubica, MD, PhD (1) · Konstantinos Koskinas, MD (1) · Lars Gullestad, MD, PhD (1) · Marian Goicoechea, MD, PhD (1) · Stephan Windecker, Prof., MD (1)
PMID 33078867, PMID 24014831, PMID 11277825, PMID 16226162, PMID 25282520, PMID 25773607, PMID 26578202, PMID 26999484, PMID 27039291, PMID 27066336, PMID 27264224, PMID 28304224, PMID 28477848, PMID 28844508, PMID 28859947, PMID 28927706, PMID 29066265, PMID 29133605, PMID 29530884, PMID 29626068, PMID 29898218, PMID 30540337, PMID 30586750, PMID 30851062, PMID 30897995, PMID 30953107, PMID 31116355, PMID 31196453, PMID 31479722, PMID 31748467, PMID 32268367, PMID 32312223, PMID 32318641, PMID 32347885, PMID 32347887, PMID 32393252, PMID 32432684, PMID 32445429, PMID 32785614, PMID 33197560, PMID 33980763, PMID 34537830, PMID 35209731, PMID 35431172, PMID 36007987, PMID 36435949, PMID 36585131, PMID 36653090, PMID 36779348, PMID 38934968
2015 (6), 2014 (3), 2017 (3), 2016 (1), 2018 (1), 2023 (1)